(PHAR)
0.00
0.00 (0.00%)
Get all premium features to the best stock analysis tool
0.00
0.00 (0.00%)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. It has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
There is no data to display
| Date | Type | Document |
|---|---|---|
| 2026-02-02 | 6-K | pharminggroupreceivescompl.htm |
| 2026-01-08 | 6-K | pharminggroupreportsprelim.htm |
| 2025-11-06 | 6-K | a2025q3pressrelease.htm |
| 2025-10-22 | 6-K | pharminggroupannouncespres.htm |
| 2025-10-06 | 6-K | pharminggroupprovidesupdat.htm |
| 2025-10-01 | 6-K | pharminggroupannouncesusfd.htm |
| 2025-09-10 | 6-K | pharminggrouppromotedtothe.htm |
| 2025-09-02 | 6-K | pharminggroupappointskenne.htm |
| 2025-07-31 | 6-K | a2025hy1pressrelease.htm |
| 2025-06-24 | 6-K | pharminggrouptohostwebcast.htm |